camptothecin has been researched along with Ebola Hemorrhagic Fever in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Basler, C; Benner, C; Bouvier, N; Bukreyev, A; Campisi, L; Chen, X; Edwards, M; Fenouil, R; García-Sastre, A; Heinz, S; Ho, JSY; Jin, J; Jordan, S; Lagda, AC; Marazzi, I; Martinez-Gil, L; Merad, M; Metreveli, G; Munoz-Fontela, C; Peralta, Z; Pietzsch, C; Rialdi, A; van Bakel, H; Weirauch, M; Zhao, N | 1 |
1 other study(ies) available for camptothecin and Ebola Hemorrhagic Fever
| Article | Year |
|---|---|
Topoisomerase 1 inhibition suppresses inflammatory genes and protects from death by inflammation.
Topics: Animals; Azepines; Camptothecin; DNA Topoisomerases, Type I; Ebolavirus; Flavonoids; Gene Expression Regulation; HEK293 Cells; Hemorrhagic Fever, Ebola; Host-Pathogen Interactions; Humans; Immunity, Innate; Inflammation; Influenza A virus; Interferon-beta; Mice; Mice, Inbred C57BL; Piperidines; Positive Transcriptional Elongation Factor B; RNA Polymerase II; Sendai virus; Staphylococcal Infections; Staphylococcus aureus; Topoisomerase I Inhibitors; Topotecan; Transcription, Genetic; Triazoles | 2016 |